



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Group")

Timing of FY results announcement

4 December 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, confirms that, due to the logistics of the auditors sign-off, there will be a short delay in the publication of the FY results. The Directors anticipate that the signing-off of the accounts and in turn, the issue of the FY Results announcement, will happen later today.

-Ends-

For more information please contact:

SkinBioTherapeutics plc	+44 (0) 191 495 7325
Stuart J. Ashman, CEO	
Manprit Randhawa, CFO	
Cavendish Capital Markets Limited	+44 (0) 20 7397 8900
(Nominated Adviser & Broker)	
Giles Balleny, Dan Hodgkinson (Corporate Finance)	
Charlie Combe (Broking)	
Dale Bellis, Tamar Cranford-Smith (Sales)	
Vigo Consulting (financial press)	+44 (0) 20 7390 0231
Rozi Morris	+44 (0) 7740 859 962
	Skinbio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

END

NORDDBDDUSGDGSX